Kylie Shackleton

582 total citations
8 papers, 50 citations indexed

About

Kylie Shackleton is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Kylie Shackleton has authored 8 papers receiving a total of 50 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Public Health, Environmental and Occupational Health and 3 papers in Genetics. Recurrent topics in Kylie Shackleton's work include BRCA gene mutations in cancer (3 papers), Cancer Genomics and Diagnostics (3 papers) and Advanced Breast Cancer Therapies (2 papers). Kylie Shackleton is often cited by papers focused on BRCA gene mutations in cancer (3 papers), Cancer Genomics and Diagnostics (3 papers) and Advanced Breast Cancer Therapies (2 papers). Kylie Shackleton collaborates with scholars based in Australia and Germany. Kylie Shackleton's co-authors include Geoffrey J. Lindeman, G. Bruce Mann, Danny Liew, Kate Burbury, Alice R.T. Bergin, Meinir Krishnasamy, Sarah Sawyer, S.J. Harris, Melissa C. Southey and Jayesh Desai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Breast.

In The Last Decade

Kylie Shackleton

8 papers receiving 50 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kylie Shackleton Australia	5	20	18	14	14	11	8	50
Anna Öfverholm Sweden	5	23 1.1×	36 2.0×	12 0.9×	13 0.9×	3 0.3×	8	71
Tara E. Soumerai United States	6	33 1.6×	8 0.4×	28 2.0×	8 0.6×	8 0.7×	11	73
BK Smruti India	6	25 1.3×	14 0.8×	6 0.4×	13 0.9×	4 0.4×	11	74
Susan Hasanpour‐Heidari Iran	6	70 3.5×	12 0.7×	15 1.1×	20 1.4×	5 0.5×	13	111
Viola Heinzelmann Switzerland	4	22 1.1×	11 0.6×	11 0.8×	4 0.3×	4 0.4×	9	67
Danielle Pendrick United States	5	13 0.7×	16 0.9×	18 1.3×	7 0.5×	4 0.4×	9	72
Lyon Mascarenhas Australia	3	11 0.6×	40 2.2×	15 1.1×	9 0.6×	6 0.5×	4	61
Francisco J. Orlandi Brazil	4	59 3.0×	17 0.9×	6 0.4×	9 0.6×	10 0.9×	8	82
Cassandra Nichols Australia	6	26 1.3×	62 3.4×	9 0.6×	23 1.6×	3 0.3×	9	111
Regina Nuccio United States	5	12 0.6×	80 4.4×	11 0.8×	20 1.4×	6 0.5×	9	117

Countries citing papers authored by Kylie Shackleton

Since Specialization

Citations

This map shows the geographic impact of Kylie Shackleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kylie Shackleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kylie Shackleton more than expected).

Fields of papers citing papers by Kylie Shackleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kylie Shackleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kylie Shackleton. The network helps show where Kylie Shackleton may publish in the future.

Co-authorship network of co-authors of Kylie Shackleton

This figure shows the co-authorship network connecting the top 25 collaborators of Kylie Shackleton. A scholar is included among the top collaborators of Kylie Shackleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kylie Shackleton. Kylie Shackleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Shackleton, Kylie, et al.. (2023). Patient communication and experiences in cancer clinical drug trials: a mixed-method study at a specialist clinical trials unit. Trials. 24(1). 400–400. 5 indexed citations

Burbury, Kate, et al.. (2020). Exploring Australian regional cancer patients’ experiences of clinical trial participation via telehealth. Journal of Telemedicine and Telecare. 28(7). 508–516. 16 indexed citations

Skandarajah, Anita, et al.. (2019). Outcomes of women at high familial risk for breast cancer: An 8‐year single‐center experience. Asia-Pacific Journal of Clinical Oncology. 16(2). e27–e37. 1 indexed citations

Lindeman, Geoffrey J., Sarah‐Jane Dawson, Jayesh Desai, et al.. (2019). Abstract PD1-06: A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2–positive metastatic breast cancer (MBC). Cancer Research. 79(4_Supplement). PD1–6. 3 indexed citations

Skandarajah, Anita, et al.. (2017). Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history. The Breast. 32. 93–97. 8 indexed citations

Lok, Sheau Wen, Alice R.T. Bergin, James R. Whittle, et al.. (2017). Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.. Journal of Clinical Oncology. 35(15_suppl). 1044–1044. 7 indexed citations

Lindeman, Geoffrey J., Emma Nolan, Bhupinder Pal, et al.. (2016). Abstract P3-11-05: RANK ligand is a target for breast cancer prevention in BRCA1 mutation carriers. Cancer Research. 76(4_Supplement). P3–11. 1 indexed citations

Teo, Zhi L., Sarah Sawyer, Paul A. James, et al.. (2013). The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia. Familial Cancer. 12(4). 587–595. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact